Abstract
Amyotrophic Lateral Sclerosis (ALS) remains one of the most difficult neurodegenerative diseases in modern medicine. Despite major advances in molecular biology, genomics, biomarker science, and regenerative medicine, patients still face a largely fatal prognosis and very limited therapeutic options.
The regulatory evaluation of emerging ALS therapies has exposed deeper tensions inside the modern FDA. Existing approval structures were largely designed around traditional pharmaceuticals, large populations, and relatively uniform disease models. ALS is none of those things. The disease progresses unevenly, patient populations are small, and therapeutic effects may emerge differently across stages of illness.
Over the past decade, the FDA has publicly embraced accelerated approval pathways, adaptive trial design, patient-focused drug development, and biomarker-driven regulation. Yet these principles have not always been applied consistently in practice.
This paper argues that ALS has become an important stress test for whether American regulatory institutions can adapt to twenty-first century biomedical science. The discussion extends beyond any single therapy or sponsor. It touches broader questions involving administrative consistency, evidentiary flexibility, patient autonomy, and the future competitiveness of the American biotechnology sector.
Using ALS therapeutics and regenerative medicine as case studies, this article examines evolving FDA policy regarding accelerated approval, Bayesian statistical methodologies, biomarker qualification, Special Protocol Assessments, and regenerative medicine oversight. It also considers the ethical consequences of regulatory delay in terminal disease.
The larger issue is no longer whether regulatory modernization is necessary. That debate has largely been settled. The issue now is whether review culture and operational decision-making will evolve quickly enough to keep pace with scientific reality.
Source: Journal of the Academy of Public Health